Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envolimab first-line monotherapy in elderly patients with PD-L1-high advanced NSCLC
ChiCTR2100046990Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- May 2021
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Objective response rate. Started May 2021; status: recruiting.
02
Drugs
envafolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100046990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046990.